APBA3 Antibody

What is APBA3/Mint3 and which antibodies are available for its detection?

APBA3/Mint3 is a protein involved in regulating glycolysis via HIF-1 activation, particularly in monocytes/macrophages, and plays a crucial role in cancer metastasis. Several validated antibodies are available:

The choice depends on your specific application and target species .

What is the observed molecular weight of APBA3 in Western blot applications?

While the calculated molecular weight of APBA3 is approximately 61 kDa, it typically appears at approximately 69-72 kDa in Western blot analysis. This discrepancy is consistent across multiple antibodies and may reflect post-translational modifications. In validation studies using human cell lines:

• HEK293, HeLa, and PC-3 cells show a specific band at approximately 69 kDa

• A431 cells also demonstrate a strong band at the expected size

Always include appropriate positive controls such as HeLa or HEK293 cell lysates when validating your antibody .

How should APBA3 antibodies be stored to maintain reactivity?

For optimal antibody performance:

• Store lyophilized antibodies at -20°C for up to one year from receipt date

• After reconstitution, store at 4°C for one month or aliquot and store at -20°C for six months

• For liquid antibodies, store at -20°C for long-term storage and at 4°C for frequent use up to one month

• Avoid repeated freeze-thaw cycles as this significantly reduces antibody activity

Some antibodies (like NBP3-06040) show stability for twelve months from date of receipt when properly stored .

What are the recommended protocols for using APBA3 antibodies in Western blot applications?

For optimal Western blot detection of APBA3:

• Sample preparation: Use 30 μg of whole cell lysate under reducing conditions

• Electrophoresis: Run on 5-20% SDS-PAGE at 70V (stacking)/90V (resolving) for 2-3 hours

• Transfer: Transfer to nitrocellulose at 150 mA for 50-90 minutes

• Blocking: Use 5% non-fat milk in TBS for 1.5 hours at room temperature

• Primary antibody incubation:

  • A07396-2: 0.5 μg/mL overnight at 4°C

  • A07396-1: 1:500-1:2000 dilution

  • Other antibodies: Follow manufacturer's recommendations

• Washing: TBS with 0.1% Tween, 3 times, 5 minutes each

• Secondary antibody: Goat anti-rabbit/mouse IgG-HRP at 1:5000-1:10000 for 1.5 hours

• Detection: Use enhanced chemiluminescence detection system

Positive controls include human HEK293, HeLa, and PC-3 whole cell lysates .

How can I optimize APBA3 detection in immunofluorescence or immunocytochemistry studies?

For successful immunofluorescence detection of APBA3:

• Fixation: Use 4% paraformaldehyde to preserve cellular structure

• Permeabilization: 0.1% Triton X-100 in PBS allows antibody access to intracellular targets

• Blocking: 10% serum (matching secondary antibody species) reduces background

• Primary antibody:

  • A07396-1: Use at 1:50-1:200 dilution

  • NBP3-06040: Use at 1:200 dilution

• Incubation: Overnight at 4°C for optimal binding

• Secondary antibody: Alexa Fluor 488-conjugated anti-rabbit/mouse IgG

• Nuclear counterstain: DAPI works well for nuclear visualization

• Expected localization: Primarily cytoplasmic staining

Validation studies with U2OS cells show clear cytoplasmic localization of APBA3 .

What controls should be included when using APBA3 antibodies in functional studies?

To ensure scientific rigor when studying APBA3 function:

• Positive tissue/cell controls:

  • Human cell lines: HEK293, HeLa, PC-3, A431

  • Mouse tissues: Consider using tissues from APBA3 knockout vs. wild-type mice

• Negative controls:

  • Primary antibody omission

  • Isotype control antibody

  • Tissues/cells from APBA3 knockout models

• Specificity validation:

  • Peptide competition assays (blocking peptides available for some antibodies)

  • siRNA knockdown or CRISPR knockout validation

  • Compare results with multiple antibodies targeting different epitopes

• Cross-reactivity assessment:

  • When studying new species, perform careful validation before proceeding with full experiments .

How can APBA3 antibodies be utilized to study metastatic niche formation?

APBA3 plays a critical role in metastatic niche formation through several mechanisms that can be investigated using specific antibodies:

• Co-localization studies:

  • Combine APBA3 antibodies with markers for inflammatory monocytes (CD115, Ly-6C, CCR2)

  • Dual staining with endothelial markers (CD31) and E-selectin

• APBA3-HIF-1 pathway analysis:

  • Use APBA3 antibodies alongside HIF-1α detection to study the pathway in tumor-associated macrophages

  • Compare expression in normoxic vs. hypoxic conditions

• Metastatic site examination:

  • Immunohistochemistry of lung sections using APBA3 antibodies (1:100-1:300) to identify infiltrating monocytes

  • Correlate with E-selectin expression in endothelial cells

• In vivo models:

  • Compare APBA3 expression in wild-type vs. knockout mouse models during metastasis

  • Analyze samples at different timepoints (4h, 24h) after tumor cell inoculation

Research has shown that host APBA3 deficiency decreases lung metastasis of B16F10, LLC, and 4T1 cancer cells by reducing E-selectin expression in lung endothelial cells .

What is the mechanism by which APBA3 promotes cancer metastasis?

APBA3 supports metastasis through a multi-step mechanism that can be studied using specific antibodies:

• Inflammatory monocyte activation:

  • APBA3 activates HIF-1 in CCR2+ inflammatory monocytes

  • This activation maintains glycolysis-dependent functions even under normoxic conditions

• VEGFA production:

  • APBA3-dependent HIF-1 activation induces VEGFA expression in monocytes

  • VEGFA can be detected using specific antibodies in conjunction with APBA3 staining

• Endothelial E-selectin induction:

  • VEGFA produced by monocytes induces E-selectin expression in endothelial cells

  • E-selectin promotes tumor cell adhesion and extravasation

• Extravasation facilitation:

  • APBA3-dependent mechanisms help tumor cells leave blood vessels and colonize target organs

  • This can be visualized using whole-mount staining with CD31 and tumor cell tracking

Research with APBA3-deficient mice shows that only 25% of tumor cells successfully invade the interstitium in APBA3-knockout lungs compared to 50% in wild-type mice .

How does APBA3 regulate glycolysis in macrophages and how can this be measured?

APBA3 regulates glycolysis in macrophages through HIF-1 activation, which can be investigated using these approaches:

• ATP production assessment:

  • APBA3 deficiency reduces ATP production in macrophages to approximately 60% of normal levels

  • Use luciferase-based ATP assays in conjunction with APBA3 antibody validation

• Glycolytic enzyme expression:

  • Compare expression of glycolytic enzymes (HK1, HK2, PFKL, LDHA) in wild-type vs. APBA3-deficient macrophages

  • Use RT-qPCR with primers specific for glycolytic enzymes (see table below)

• Metabolic flux analysis:

  • Measure extracellular acidification rate (ECAR) in macrophages with varying APBA3 expression

  • Combine with oxygen consumption rate (OCR) measurements

• 2-DG sensitivity testing:

  • APBA3-dependent macrophages are particularly sensitive to glycolysis inhibition

  • Compare the effects of 2-DG treatment on wild-type vs. APBA3-deficient cells

Studies show that APBA3-deficient mice demonstrate resistance to LPS-induced septic shock due to reduced glycolytic capacity in macrophages .

How can I troubleshoot non-specific binding when using APBA3 antibodies?

When encountering non-specific binding with APBA3 antibodies:

• Optimize blocking conditions:

  • Try different blocking agents (5% BSA, 5-10% normal serum, commercial blockers)

  • Increase blocking time to 2 hours at room temperature

• Adjust antibody concentration:

  • Perform a titration series (e.g., 1:100, 1:500, 1:1000, 1:2000)

  • For Western blot, start with 0.1-0.5 μg/ml for Picoband antibodies

• Increase washing stringency:

  • Add additional wash steps (5 instead of 3)

  • Increase Tween-20 concentration slightly (up to 0.3%)

  • Extend washing times to 10 minutes per wash

• Validate with multiple antibodies:

  • Compare results using antibodies targeting different epitopes

  • Use APBA3-knockout samples as negative controls

• Pre-absorb the antibody:

  • Incubate with non-specific proteins before application to reduce cross-reactivity

  • Consider using a blocking peptide if available .

How should I interpret differences in APBA3 expression between tumor and normal tissues?

When analyzing APBA3 expression patterns:

• Cell type-specific expression:

  • APBA3 is strongly expressed in monocytes/macrophages

  • Lower expression in other cell types is normal

  • Use dual staining with cell type-specific markers (CD68, CD11b) for proper interpretation

• Localization changes:

  • APBA3 is primarily cytoplasmic in normal cells

  • Alterations in subcellular localization may indicate functional changes

  • Compare with HIF-1α localization in the same samples

• Quantification approaches:

  • Use digital image analysis to quantify staining intensity

  • Normalize to appropriate housekeeping proteins for Western blot

  • Present data as fold-change relative to control samples

• Metastatic vs. primary tumor analysis:

  • APBA3 may show different patterns in primary tumors vs. metastatic sites

  • Focus on the tumor microenvironment, particularly infiltrating monocytes

  • E-selectin expression in endothelial cells correlates with APBA3 activity .

How can I determine if an APBA3 antibody will cross-react with tissues from species not listed in the datasheet?

When testing APBA3 antibodies in new species:

• Sequence homology analysis:

  • Compare the immunogen sequence across species using alignment tools

  • Higher homology (>80%) suggests potential cross-reactivity

• Step-wise validation:

  • Start with Western blot to confirm band at expected molecular weight

  • Proceed to IHC/IF only after Western blot validation

  • Include known positive control tissue alongside test samples

• Multiple antibody approach:

  • Test multiple antibodies targeting different epitopes

  • Concordant results increase confidence in cross-reactivity

• Knockout/knockdown controls:

  • If available, include tissue from APBA3-deficient animals of the test species

  • Alternatively, use siRNA knockdown in cultured cells from the test species

As noted in a customer question to Bosterbio, while an antibody might not be validated for a specific species (e.g., goat), cross-reactivity is possible and can be tested through an innovator award program .

How can APBA3 antibodies be used to investigate the APBA3-HIF-1 pathway in disease models?

For investigating the APBA3-HIF-1 pathway:

• Co-immunoprecipitation studies:

  • Use APBA3 antibodies to pull down protein complexes

  • Detect HIF-1α and FIH-1 (factor inhibiting HIF-1) in the immunoprecipitates

  • Compare results in normoxia vs. hypoxia

• Chromatin immunoprecipitation (ChIP):

  • Analyze HIF-1 binding to target promoters in wild-type vs. APBA3-deficient cells

  • Focus on glycolytic enzyme genes and VEGFA promoter regions

• Proximity ligation assay:

  • Detect protein-protein interactions between APBA3 and pathway components

  • Visualize interactions in situ in tissue sections

• Disease model applications:

  • Compare APBA3 expression in inflammation models (e.g., LPS-induced sepsis)

  • Analyze expression in cancer metastasis models at different timepoints

  • Correlate with disease progression and outcomes

The APBA3-HIF-1 pathway can be therapeutically targeted, as APBA3 deficiency specifically affects macrophage function without impacting other cell types significantly .

What are the considerations when designing experiments to study APBA3 in specialized cell populations?

When studying APBA3 in specific cell populations:

• Cell isolation techniques:

  • For monocytes/macrophages, use CD115, CCR2, or Ly-6C as sorting markers

  • Flow cytometry can separate inflammatory from resident macrophages

  • Magnetic bead-based isolation provides higher cell yields

• Conditional knockout approaches:

  • Use LysM-Cre for myeloid-specific APBA3 deletion

  • Compare with global APBA3 knockout to distinguish cell-autonomous effects

• In vivo tracking:

  • Label isolated cells with fluorescent dyes before adoptive transfer

  • Use reporter mice (e.g., GFP under APBA3 promoter) to track expression

• Single-cell analysis:

  • Combine APBA3 antibodies with additional markers for heterogeneity assessment

  • Consider single-cell RNA-seq to correlate APBA3 with global expression patterns

Research using myeloid-specific APBA3 knockout (LysM-Cre x APBA3-floxed) mice has confirmed that macrophage-specific APBA3 deletion recapitulates many aspects of global knockout phenotypes .

How do modifications of the APBA3 protein affect antibody recognition and function?

Understanding APBA3 modifications is crucial for antibody selection:

• Post-translational modifications:

  • Phosphorylation can alter antibody recognition

  • Western blot analysis might reveal multiple bands reflecting modified forms

  • Treat samples with phosphatases to confirm modification status

• Truncated variants:

  • APBA3-NT (amino acids 1-214) has been used in functional studies

  • Antibodies targeting different regions may yield varying results

  • Consider using antibodies against N-terminal, C-terminal, and internal regions

• Domain-specific functions:

  • APBA3 contains protein-protein interaction domains

  • Antibodies targeting specific domains might interfere with function

  • Use epitope mapping to understand antibody binding sites

• Experimental considerations:

  • For functional studies, ensure antibodies don't interfere with key interactions

  • For detection only, multiple antibodies can provide comprehensive coverage

Expression constructs for APBA3-NT and lentiviral vectors carrying APBA3 cDNA can be useful tools for functional validation .